Chongqing Pharscin Pharmaceutical (002907.SZ) obtained the drug registration certificate for gefitinib capsules.

Chongqing Pharscin Pharmaceutical (002907.SZ) announced that the company has received the "Drug Registration Certificate" for its product Crizotinib Capsules issued by the National Medical Products Administration. The Crizotinib Capsules were introduced to the Chinese market in 2013, and in 2018, they were included in the medical insurance list. The drug has accumulated over ten years of clinical application experience. It is mainly used in the clinical treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positivity, as well as in advanced NSCLC patients with ROS1 positivity.